Study for the ARRT Radiation Therapy examination by pairing every concept with its assumptions: PDD with SSD setups, TMR with isocentric setups, each beam modifier with the dose problem it fixes, and each patient reaction with the graded severity and protocol response it requires. Work scenarios where a plausible mistake is named and corrected, then audit yourself with a setup-assignment drill until you can state each quantity's geometry from memory.
Why PDD, TMR, and TAR Belong to Different Setup Geometries
Percent depth dose (PDD) describes a beam measured in an SSD geometry and normalized at dmax, while TMR and TPR describe isocentric (SAD) geometry. Matching the quantity to the setup is the core decision in dose calculation questions.
PDD is the ratio of dose at a depth to dose at dmax on the same central axis, measured with a fixed source-surface distance, and it varies with energy, depth, field size, and SSD. TMR instead compares dose at a depth in tissue to dose at dmax in tissue at the same source-axis distance, which suits isocentric techniques where the SSD changes with depth. TAR, an older quantity, relates dose in tissue to dose in air at the same point. Trace each definition to its measurement setup before memorizing any table.
Worked scenario: an isocentric two-field lung plan needs monitor units at 8 cm depth. A plausible mistake is plugging a PDD value directly from an SSD table into the SAD calculation. The better decision is to recognize the isocentric geometry, reach for TMR-based data, or convert PDD with an inverse-square correction. In a textbook-style illustration, a 6 MV beam with a PDD of roughly 0.715 at 8 cm is an SSD-table number; using it uncorrected in an SAD setup mis-scales both the depth-dose falloff and the inverse-square term, so the calculated dose drifts from what the beam actually delivers. The illustrative value demonstrates the method; real machine data belong to your own beam.
Choosing Between Bolus, Wedges, and Compensators
Bolus builds dose up at the surface, wedges tilt isodose distributions across a field, and compensators restore attenuation lost to missing tissue on irregular contours. Choose by identifying which part of the dose distribution must change.
Bolus is tissue-equivalent material placed on the skin that moves dmax toward the surface, used when a target sits at or near the skin, as in some chest wall or scalp treatments. A wedge changes the dose gradient across a field, compensating for oblique incidence or shaping a tilted isodose distribution; physical wedges sit in the beam while dynamic wedges achieve the effect through jaw motion. A compensator approximates missing tissue attenuation for an irregular surface while largely preserving the skin-sparing behavior of the beam.
Decision example: a post-mastectomy chest wall plan where the scar requires a surface dose boost. A plausible mistake is applying bolus across the entire field, raising surface dose everywhere the target may not need it. The better decision is to place bolus only over the region the plan identifies as needing surface dose, or use the plan's prescribed modifier combination, and verify the choice against the prescription. Compare the three modifiers with the table below, and note that the clinical plan and prescription, not habit, determine the answer.
| Modifier | What it changes | Trigger in a plan | Mismatch to check |
|---|---|---|---|
| Bolus | Moves dmax toward the skin surface | Target at or near the skin | Bolus applied where skin sparing was intended |
| Wedge | Tilts the isodose distribution across the field | Oblique incidence or asymmetric dose needed | Wedge orientation and dose gradient direction |
| Compensator | Replaces missing-tissue attenuation | Irregular surface contour | Whether skin sparing is preserved as intended |
Converting Fractionation Schedules with BED Instead of Guessing
Biologically effective dose, BED = nd(1 + d/(α/β)), puts schedules with different fraction sizes on a comparable scale. Tissues with low α/β are more sensitive to fraction size than tissues modeled with high α/β.
In the formula, n is the number of fractions, d the dose per fraction, and α/β a tissue-specific model parameter. Textbook teaching values place most tumors and early-responding tissues near 10 Gy and late-responding tissues near 3 Gy; these are modeling assumptions, not fixed constants. A labeled example: 2 Gy × 30 gives a physical dose of 60 Gy and tumor BED = 60 × (1 + 2/10) = 72 Gy10, while 3 Gy × 20 also gives 60 Gy but tumor BED = 60 × (1 + 3/10) = 78 Gy10. Same physical dose, different model estimate.
Worked scenario: comparing the same two schedules for late effects using an α/β of 3. A plausible mistake is treating both 60 Gy prescriptions as equivalent without checking fraction size. The better decision is to compute late-effect BED: 2 Gy × 30 yields 60 × (1 + 2/3) = 100 Gy3, while 3 Gy × 20 yields 60 × (1 + 3/3) = 120 Gy3, a substantially higher late-effect estimate. Why it matters: fraction size, not just total dose, drives the model's prediction for late-responding tissue, and BED itself is a linear-quadratic construct whose use is limited to the range where that model applies.
Evaluating a Plan and Verifying Delivery Before the First Fraction
Plan evaluation means reading isodose distributions and dose-volume summaries against the prescription and objectives for targets and organs at risk, then confirming delivery through pre-treatment checks appropriate to the technique.
On an isodose display, check that the prescription isodose covers the target as intended, note where hot spots sit and whether they fall inside the target or in normal tissue, and look for cold regions, especially near critical structures. Conformal plans are judged largely on isodose shape, while modulated techniques are judged on dose-volume metrics because the fluence is deliberately nonuniform. Knowing which evaluation lens fits the technique is itself a testable skill.
Verification follows a chain: patient-specific checks for modulated plans confirm that planned fluence maps to delivered fluence before treatment starts; pre-treatment imaging establishes daily shifts; record-and-verify systems gate each session. Trace a head and neck example: weekly imaging and weight tracking reveal contour change over the course. A plausible mistake is treating the shift decision as independent; the better decision is to document and escalate, because plan adaptation is a physician-led review, not a technologist's solo adjustment. Each chain step catches a different failure, so learn what each one exists to detect.
Managing Skin Reactions at the Right Severity Step
Assess the treated area at every visit, match the observation to a graded severity, and escalate per protocol. Moist desquamation calls for non-adherent, moisture-retentive dressings and documentation, not adhesive materials or unreported findings.
Skin reactions in the treated field typically progress from erythema to dry desquamation to moist desquamation. Care principles at the paper-scenario level: gentle cleansing, avoiding known irritants on the field, non-adherent dressings for broken skin, and consistent documentation of location and extent so trends are visible across fractions. The severity grade drives both the response and who needs to be notified, so grading is not paperwork — it is the decision point.
Worked scenario: on day 22 of a chest wall course, a patient reports weeping skin in the inframammary fold. A plausible mistake is covering it with adhesive tape and telling the patient it will dry out, without documenting or reporting. The better decision is to recognize moist desquamation, apply the department's skin-care protocol for that severity, flag the finding for physician review, and record it in the treatment record. Why it matters: adhesive removal strips fragile epithelium, and untracked worsening can threaten both patient comfort and treatment continuity. This is a paper scenario for practice — in clinical settings, your institution's protocol governs each step.
Separating Stage, Grade, and Treatment Intent in Clinical Stems
Stage describes anatomic extent through TNM categories, grade describes how abnormal tumor cells appear microscopically, and intent separates curative from palliative goals. Decide which concept a question stem is actually testing before answering.
TNM staging records T for primary tumor extent, N for nodal involvement, and M for distant metastases, which combine into stage groupings. Grade reflects differentiation — how closely tumor cells resemble normal tissue — and describes behavior at the cellular level rather than anatomic spread. Trace an example: two tumors of the same type and same T category differ in nodal status, so their stage groupings and typical management differ even though grade could be identical. Confusing the two axes produces wrong answers even with correct recall.
Intent shapes everything downstream: definitive courses pursue durable control with full prescription doses, while palliative courses aim at symptom relief with shorter schedules. A plausible mistake on a palliative spine case is importing curative-course logic, such as agonizing over constraints framed for definitive treatment, or the reverse, under-evaluating a curative case because the schedule looks short. The better decision is to identify the stated goal first, then evaluate each option against that goal. This ordering habit resolves many clinical stems faster than memorizing treatment lists.
A Setup-Assignment Drill and Adaptable Preparation Sequence
Run a drill that forces you to name each quantity's geometry before computing, then rotate through the content domains with an error log. Readiness means explaining every item aloud without notes, verified against your rubric.
The drill: build one-page cards for PDD, TMR, TPR, TAR, wedge factors, and output factors. Each card must state the measurement geometry, the normalization point, and what changes the value. Then take ten textbook-style calculation problems and tag each with its geometry before doing any arithmetic. Expected observations: on your first set you catch at least one geometry mismatch you would previously have missed; by the third set you tag all ten correctly and can state each card's content from memory. If a card stays blank after two attempts, that quantity is your next study target.
Adaptable sequence over four to eight weeks, reordered to start with your weakest domain: first, physics quantities and calculations; second, planning, dosimetry, and beam modifiers; third, delivery verification and quality management concepts; fourth, clinical oncology, staging, and intent; fifth, patient care and toxicity grading; sixth, mixed timed sets with error-log review. The error log matters more than the schedule — every miss gets a one-line cause. Treat the self-check scores below as learning milestones, not predictions of any outcome.
- Rubric each domain 0-3: 0 = cannot answer, 1 = vague recall, 2 = correct with notes, 3 = correct explained aloud; a 2 or higher in every domain is a milestone.
- Reproduce the BED formula and compute both tumor and late-effect BED for two different schedules without notes.
- For any dose quantity, state its geometry and normalization point in one sentence.
- Given a described dose-distribution problem, name the modifier that addresses it and the mismatch to verify.
- Grade a described skin observation and name the protocol-level next step.
- Trace the verification chain — planning data, pre-treatment checks, imaging shifts, record-and-verify — and say what failure each step detects.
References and further reading
Use these references to explore the concepts and check the latest information from the relevant organizations.